

ENTYVIO (VEDOLIZUMAB) ORDERS

P: 877.365.5566 | **F:** 855.889.2946

A Carelon Company

PATIENT INFORMATION: Fax completed form, insurance information, and clinical documentation to 855.889.2946

Patient Name: _______ DOB: ______ Phone: ______

Patient Name:	DOB: Phone:
Patient Status: ☐ New to Therapy ☐ Continuing Therapy	Next Treatment Date:
MEDICAL INFORMATION	
Diagnosis: ☐ Crohn's Disease ☐ Ulcerative Colitis ☐ C	Other:
ICD-10 Code:	
Patient weight: lbs. Allergies:	
THERAPY ORDER	
Entyvio IV: ☐ Initial start: 300mg IV at 0, 2, 6, then every 8 weeks x1 year ☐ 300mg IV every 8 weeks x1 year ☐ 300mg IV every weeks x1 year Entyvio IV to subQ	
☐ IV induction dose: 300mg IV at week 0 and 2	
Lab Orders: Frequency: □ Perform TB QFT testing yearly (optional)	
Required labs to be drawn by: 🔲 Infusion Center 🔲 R	Referring Provider
Other orders:	
Home IV Biologic Ana-kit Orders (adult): • Epinephrine: >30kg (>66lbs): EpiPen 0.3mg or compounded so Diphenhydramine: Administer 25-50mg orally OR IV (adult)	yringe IM or subQ; may repeat in 5-10 minutes x1

• NS 0.9% 1000mL IV bolus per protocol PRN (adult)

Home biologic injection Ana-kit (adult):

• Dispense per protocol EpiPen 0.3mg IM (2-pack)

Refer to physician order or institutional protocol for pediatric dosing Ana-kit

Flush orders: NS 1-20mL pre/post infusion PRN and Heparin 10U/mL or 100U/mL per protocol as indicated PRN

PROVIDER INFORMATION

By signing this form and utilizing our services, you are authorizing Paragon Healthcare, Inc. and its employees to serve as your prior authorization and specialty pharmacy designated agent in dealing with medical and prescription insurance companies, and to select the preferred site of care for the patient.

Provider Name:

Signature:

Date:

Provider NPI: _____ Phone: _____ Fax: _____ Contact Person:

 \square Opt out of Paragon selecting site of care (if checked, please list site of care):

PREFERRED LOCATION

ity: ______ State: _____ View our locations here:



PARAGONHEALTHCARE.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.





COMPREHENSIVE SUPPORT FOR ENTYVIO (VEDOLIZUMAB) THERAPY

A Carelon Company

PATIENT INFORMATION:
Patient Name: DOB:
REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVAL
\square Include <u>signed</u> and <u>completed</u> order (MD/prescriber to complete page 1)
☐ Include patient demographic information and insurance information
☐ Include patient's medication list
☐ Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits, or contraindications to conventional therapy
☐ Has the patient had a documented contraindication/intolerance or failed trial of a corticosteroid or immunomodulator? ☐ Yes ☐ No If yes, which drug(s)?
□ Does the patient have a contraindication/intolerance or failed trial to at least one biologic (i.e., Humira, Stelara, Cimzia, infliximab)? □ Yes □ No If yes, which drug(s)?
☐ Include labs and/or test results to support diagnosis
☐ If applicable - Last known biological therapy: and last date received: If patient is switching to biologic therapies, please perform a washout period of weeks prior to starting Entyvio.
☐ Other medical necessity:
REQUIRED PRE-SCREENING
☐ TB screening test (completed within 12 months for new start) - attach results ☐ Positive ☐ Negative
\square LFTs - can be drawn with first infusion if not available
*If TB results are positive - please provide documentation of treatment or medical clearance, and a negative CXR

Paragon Healthcare will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

Please fax all information to (855) 889-2946 or call (877) 365-5566 for assistance